The hype from Elon Musk has been coming for weeks: This Friday, his secretive brain-implants startup Neuralink will give the first major update on its progress in more than a year. Whatever Neuralink unveils, it follows years of internal conflict in which rushed timelines have clashed with the slow and incremental pace of science, a STAT examination has found.

Four former employees described a chaotic internal culture — typical of Musk’s companies — characterized by intense demands and a sometimes haphazard rush to carry out projects and, just as quickly, to kill them. The company is now down to just three of its eight original founding scientists. And its researchers have long talked privately about the need to scale back elements of the company’s sweeping ambitions to focus on simpler, more targeted applications of its technology to make quicker progress, according to two former employees.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy